1. Home
  2. PCVX vs CRSP Comparison

PCVX vs CRSP Comparison

Compare PCVX & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$47.53

Market Cap

6.1B

Sector

Health Care

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$57.28

Market Cap

5.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCVX
CRSP
Founded
2013
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1B
5.1B
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
PCVX
CRSP
Price
$47.53
$57.28
Analyst Decision
Strong Buy
Buy
Analyst Count
7
19
Target Price
$105.00
$71.50
AVG Volume (30 Days)
1.2M
1.7M
Earning Date
02-24-2026
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$38,337,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,299.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.66
$30.04
52 Week High
$93.77
$78.48

Technical Indicators

Market Signals
Indicator
PCVX
CRSP
Relative Strength Index (RSI) 59.10 54.68
Support Level $44.57 $53.37
Resistance Level $47.72 $60.73
Average True Range (ATR) 2.00 2.39
MACD 0.10 0.22
Stochastic Oscillator 75.11 61.53

Price Performance

Historical Comparison
PCVX
CRSP

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: